The Aging Research & Drug Discovery (ARDD) 2026 conference, a cornerstone event in longevity science, has been unexpectedly canceled in Copenhagen, prompting swift reactions from the research community. Professor Morten Scheibye-Knudsen announced the news on LinkedIn, expressing dismay over the University of Copenhagen’s decision, which has disrupted years of collaboration and planning among leading figures in academia and biotech.

This cancellation highlights the fragility of partnerships within the longevity field, particularly as the conference has become a pivotal venue for discussing advancements in aging therapeutics, including the growing interest in GLP-1s as potential longevity drugs. With the event’s relocation to Boston Longevity Week, organizers aim to maintain momentum by focusing on the pharmaceutical sector, promising a concentrated gathering of industry leaders and innovators.

For longevity professionals, this shift underscores the importance of adaptability in the face of unforeseen challenges. I encourage you to read the full story for insights into the future of the ARDD conference and the evolving landscape of longevity research.

Source: longevity.technology